barium selenate
elanco australasia pty ltd - barium selenate - unknown - barium selenate ungrouped active 0.0 - active constituent
barium selenate
elanco australasia pty ltd - barium selenate - unknown - barium selenate ungrouped active 0.0 - active constituent
barium selenate
abbey laboratories pty ltd - barium selenate - unknown - barium selenate ungrouped active 0.0 - active constituent
barium selenate
abbey laboratories pty ltd - barium selenate - unknown - barium selenate ungrouped active 0.0 - active constituent
selovin la
elanco new zealand - barium selenate - barium selenate 177.48 g/litre - parenteral nutrient/electrolyte
selovin la long acting selenium injection for cattle and sheep
elanco australasia pty ltd - selenium as barium selenate - parenteral liquid/solution/suspension - selenium as barium selenate mineral-selenium active 50.0 mg/ml - nutrition & metabolism - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - selenium deficiency | white muscle disease
smartshot b12 plus selenium
agresearch ltd - barium selenate; hydroxocobalamin hydrochloride - barium selenate 42.6 g/litre; hydroxocobalamin hydrochloride 3 g/litre - parenteral nutrient/electrolyte
barium chloride liquid (s#128)
total health centre - barium chloride - liquid - 6x - barium chloride 6x - homeopathic products
smartshot selenium
agresearch ltd - selenium present as barium selenate - selenium present as barium selenate 24 g/litre - parenteral nutrient/electrolyte
tagitol v- barium sulfate suspension
e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - tagitol v is indicated for use in adult patients for use in computed tomography (ct) colonography as a fecal tagging agent. tagitol v is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract; - known obstruction of the gi tract; - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis; - high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation; - known hypersensitivity to barium sulfate or any of the excipients of tagitol v. risk summary tagitolv is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary tagitol v is not absorbed systemically by the mother following oral administration and breastfeedin